Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

SANDOSTATIN

Package(a):
AMPOULES (solution for injection/infusion) : 5 x 0.05 mg/ml.
Dosage(a):
See prescribing information for full details.
Prescribing Restrictions:     

Package(b):
VIAL (solution for injection/infusion): 1 x 0.2 mg/ml.
Dosage(b):
Initially: 0.05 mg 1-2 x daily S.C. Gradually increase to 0.2 mg 3 x daily. Maintenance doses are variable. See prescribing information for full details.
Prescribing Restrictions:     
 
Package(c):
AMPOULES (solution for injection/infusion): 5 x 0.1 mg/ml.
Dosage(c):
See prescribing information for full details.
Prescribing Restrictions:     
 
Package(d):
AMPOULES (solution for injection/infusion): 5 x 0.5 mg/ml.
Dosage(d):
See prescribing information for full details.
Prescribing Restrictions:      


Indications:
Prevention of complications following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastro-entero-pancreatic endocrine tumors: Carcinoid tumors with features of carcinoid syndrome; VIPomas; glucagonomas; gastrinomas/Zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors, H₂-antagonist therapy; insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy; GRFomas. Sandostatin is not an antitumor therapy and is not curative in these patients. Emergency management of bleeding gastro-esophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
Contra-Indications:
Hypersensitivity.
Special Precautions:
The elimination capacity may by reduced in patients with liver cirrhosis, but not in patients with fatty liver disease. In patients with impaired liver cirrchosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage. It is recommended that the solution reaches room temperature before injection. Multiple injections at short intervals at the same site should be avoided. It is essential that all patients be carefully monitored. Ultrasonic examination of the gallbladder before and at about 6-monthly intervals during therapy is recommended. In the treatment of gastroenteropancreatic endocrine tumors sudden escape from symptomatic control may occur infrequently, with rapid recurrence of severe symptoms. Patients with insulinomas, octeotide should be closely monitored on introduction of therapy and at each change of dosage. Patients with type I diabetes mellitus requiring insulin therapy may have their insulin requirements reduced. In non-diabetics and type II diabetics with partially intact insulin reserves, administration can result in prandial increases in glycemia. Pregnancy and lactation: Drug should be given only under compelling circumstances.
Side Effects:
Pain or a sensation of stinging, tingling or burning at the site of S.C. injection. Hypersensitivity, skin reactions, transient hair loss, isolated cases of bradycardia, prolonged use may result in gallstone formation. Anorexia, nausea, vomiting, crampy abdominal pain, abdominal bloating, flatulence, loose stools, steatorrhea. May impair postprandial glucose tolerance with chronic administration, hypoglycemia, isolated reports of hepatic dysfunctions. See prescribing information for full details.
Drug Interactions:
Corticosteroids, diazoxide, thiazide, diuretics, or dextrose, bromocriptine. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should therefore be used with caution.